Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma
Advanced hepatocellular carcinoma (HCC) remains a fatal disease even in the era of targeted therapies. Intra-arterial chemotherapy (IACT) can provide therapeutic benefits for patients with locally advanced HCC who are not eligible for local therapies or are refractory to targeted therapies. The aim...
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2014-01-01
|
| Series: | The Scientific World Journal |
| Online Access: | http://dx.doi.org/10.1155/2014/160138 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550092133892096 |
|---|---|
| author | Ming-Chun Ma Yen-Yang Chen Shau-Hsuan Li Yu-Fan Cheng Chih-Chi Wang Tai-Jan Chiu Sung-Nan Pei Chien-Ting Liu Tai-Lin Huang Chen-Hua Huang Yu-Li Su Yen-Hao Chen Sheng-Nan Lu Kun-Ming Rau |
| author_facet | Ming-Chun Ma Yen-Yang Chen Shau-Hsuan Li Yu-Fan Cheng Chih-Chi Wang Tai-Jan Chiu Sung-Nan Pei Chien-Ting Liu Tai-Lin Huang Chen-Hua Huang Yu-Li Su Yen-Hao Chen Sheng-Nan Lu Kun-Ming Rau |
| author_sort | Ming-Chun Ma |
| collection | DOAJ |
| description | Advanced hepatocellular carcinoma (HCC) remains a fatal disease even in the era of targeted therapies. Intra-arterial chemotherapy (IACT) can provide therapeutic benefits for patients with locally advanced HCC who are not eligible for local therapies or are refractory to targeted therapies. The aim of this retrospective study was to analyze the effect of IACT with cisplatin and doxorubicin on advanced HCC. Methods. Patients with advanced HCC who were not eligible for local therapies or were refractory to sorafenib received doxorubicin (50 mg/m2) and cisplatin (50 mg/m2) infusions into the liver via the transhepatic artery. Between January 2005 and December 2011, a total of 50 patients with advanced HCC received this treatment regimen. The overall response rate (ORR) was 22% in all treated patients. In patients who received at least 2 cycles of IACT, the ORR was 36.7%, and the disease control rate was 70%. Survival rate differed significantly between patients who received only one cycle of IACT (group I) and those who received several cycles (group II). The median progression-free survival was 1.3 months and 5.8 months in groups I and II, respectively (P<0.0001). The median overall survival was 8.3 months for all patients and was 3.1 months and 12.0 months in groups I and II, respectively (P<0.0001). The most common toxicity was alopecia. Four patients developed grade 3 or 4 leukopenia. Worsening of liver function, nausea, and vomiting were uncommon side effects. This study demonstrated clinical efficacy and tolerable side effects of repeated IACT with doxorubicin and cisplatin in advanced HCC. Our regimen can be an alternative choice for patients with adequate liver function who do not want to receive continuous infusion of IACT. |
| format | Article |
| id | doaj-art-ab659e552f0f4e688c24d611400d53df |
| institution | Kabale University |
| issn | 2356-6140 1537-744X |
| language | English |
| publishDate | 2014-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | The Scientific World Journal |
| spelling | doaj-art-ab659e552f0f4e688c24d611400d53df2025-02-03T06:07:51ZengWileyThe Scientific World Journal2356-61401537-744X2014-01-01201410.1155/2014/160138160138Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell CarcinomaMing-Chun Ma0Yen-Yang Chen1Shau-Hsuan Li2Yu-Fan Cheng3Chih-Chi Wang4Tai-Jan Chiu5Sung-Nan Pei6Chien-Ting Liu7Tai-Lin Huang8Chen-Hua Huang9Yu-Li Su10Yen-Hao Chen11Sheng-Nan Lu12Kun-Ming Rau13Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, TaiwanCollege of Medicine, Chang Gung University, Kaohsiung 333, TaiwanCollege of Medicine, Chang Gung University, Kaohsiung 333, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, TaiwanCollege of Medicine, Chang Gung University, Kaohsiung 333, TaiwanDivision of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang Gung Memorial Hospital, 123 Ta-Pei Road, Niaosong District, Kaohsiung 833, TaiwanAdvanced hepatocellular carcinoma (HCC) remains a fatal disease even in the era of targeted therapies. Intra-arterial chemotherapy (IACT) can provide therapeutic benefits for patients with locally advanced HCC who are not eligible for local therapies or are refractory to targeted therapies. The aim of this retrospective study was to analyze the effect of IACT with cisplatin and doxorubicin on advanced HCC. Methods. Patients with advanced HCC who were not eligible for local therapies or were refractory to sorafenib received doxorubicin (50 mg/m2) and cisplatin (50 mg/m2) infusions into the liver via the transhepatic artery. Between January 2005 and December 2011, a total of 50 patients with advanced HCC received this treatment regimen. The overall response rate (ORR) was 22% in all treated patients. In patients who received at least 2 cycles of IACT, the ORR was 36.7%, and the disease control rate was 70%. Survival rate differed significantly between patients who received only one cycle of IACT (group I) and those who received several cycles (group II). The median progression-free survival was 1.3 months and 5.8 months in groups I and II, respectively (P<0.0001). The median overall survival was 8.3 months for all patients and was 3.1 months and 12.0 months in groups I and II, respectively (P<0.0001). The most common toxicity was alopecia. Four patients developed grade 3 or 4 leukopenia. Worsening of liver function, nausea, and vomiting were uncommon side effects. This study demonstrated clinical efficacy and tolerable side effects of repeated IACT with doxorubicin and cisplatin in advanced HCC. Our regimen can be an alternative choice for patients with adequate liver function who do not want to receive continuous infusion of IACT.http://dx.doi.org/10.1155/2014/160138 |
| spellingShingle | Ming-Chun Ma Yen-Yang Chen Shau-Hsuan Li Yu-Fan Cheng Chih-Chi Wang Tai-Jan Chiu Sung-Nan Pei Chien-Ting Liu Tai-Lin Huang Chen-Hua Huang Yu-Li Su Yen-Hao Chen Sheng-Nan Lu Kun-Ming Rau Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma The Scientific World Journal |
| title | Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma |
| title_full | Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma |
| title_fullStr | Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma |
| title_full_unstemmed | Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma |
| title_short | Intra-Arterial Chemotherapy with Doxorubicin and Cisplatin Is Effective for Advanced Hepatocellular Cell Carcinoma |
| title_sort | intra arterial chemotherapy with doxorubicin and cisplatin is effective for advanced hepatocellular cell carcinoma |
| url | http://dx.doi.org/10.1155/2014/160138 |
| work_keys_str_mv | AT mingchunma intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT yenyangchen intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT shauhsuanli intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT yufancheng intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT chihchiwang intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT taijanchiu intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT sungnanpei intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT chientingliu intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT tailinhuang intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT chenhuahuang intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT yulisu intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT yenhaochen intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT shengnanlu intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma AT kunmingrau intraarterialchemotherapywithdoxorubicinandcisplatiniseffectiveforadvancedhepatocellularcellcarcinoma |